The long term goal of the proposed studies is to define the molecular mechanisms of the procoagulant regulation of human prothrombin activation by factor Va, and the mechanism of the anticoagulant inactivation of factor Va by the protein C system. The studies address significant gaps in the understanding of three mechanisms: factor V activation, factor Va cofactor activity, and factor Va inactivation. In factor V activation, interactions of factor V and its activation products with exosites I and II of thrombin are hypothesized to mediate recognition of factor V as a substrate and to direct the activation pathway. In the hypothesis for the mechanism of factor Va cofactor activity, the rate and pathway of prothrombin activation are regulated by binding of prothrombin, the activation intermediates, and thrombin to the same site on factor Va in the factor Xa-factor Va complex, in interactions mediated primarily by exosite I present in a low affinity, precursor state on prothrombin (proexosite I). The interactions are modulated by differential expression of the high affinity state of exosite I on the prothrombin activation intermediates, and by interactions of fragment 2 and membranes. Regulation of factor Va inactivation by activated protein C (aPC) and the anticoagulant activity of protein S are hypothesized to result from the interdependence of the assembly of membrane-bound aPC-factor Va- protein S complexes and factor Xa-factor Va complexes. The hypotheses will be evaluated by a combination of equilibrium binding studies of the interactions employing fluorescence techniques, kinetic studies of the proteolytic reactions, and protein structural studies.
Specific aims are: (1) To define the roles of regulatory exosites I and II of thrombin in the mechanism of factor V activation; (2) To determine the mechanism of expression of exosites I and II in the conversion of prothrombin to thrombin and the expression of linkage between the exosites; (3) To define the mechanism of involvement of (pro)exosite I, fragment 2 and membranes in factor Va interactions with prothrombin and its activation products, and the roles of these interactions in factor Va cofactor activity; and (4) To elucidate the mechanism of regulation of factor Va inactivation by aPC involving assembly of membrane-bound factor Xa-factor Va complexes and aPC-factor Va-protein S interactions. The results of the studies are expected to have significance in advancing the understanding of normal hemostatic mechanisms and the molecular pathology of thrombotic vascular disease. Information derived from these studies may provide new molecular targets for anticoagulant therapy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL038779-15
Application #
6530639
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Link, Rebecca P
Project Start
1994-04-01
Project End
2003-03-31
Budget Start
2002-03-01
Budget End
2003-03-31
Support Year
15
Fiscal Year
2002
Total Cost
$248,695
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pathology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Tormoen, Garth W; Cianchetti, Flor A; Bock, Paul E et al. (2012) Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Front Oncol 2:110
Kroh, Heather K; Panizzi, Peter; Tchaikovski, Svetlana et al. (2011) Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo. J Biol Chem 286:23345-56
Berny-Lang, M A; Aslan, J E; Tormoen, G W et al. (2011) Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol 8:015014
Newell-Caito, Jennifer L; Laha, Malabika; Tharp, Anthony C et al. (2011) Notecarin D binds human factor V and factor Va with high affinity in the absence of membranes. J Biol Chem 286:38286-97
Tormoen, G W; Rugonyi, S; Gruber, A et al. (2011) The role of carrier number on the procoagulant activity of tissue factor in blood and plasma. Phys Biol 8:066005
Panizzi, Peter; Nahrendorf, Matthias; Figueiredo, Jose-Luiz et al. (2011) In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat Med 17:1142-6
Corral-Rodriguez, Maria Angeles; Bock, Paul E; Hernandez-Carvajal, Erick et al. (2011) Structural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junction. Blood 117:7164-73
Nicolaes, Gerry A F; Bock, Paul E; Segers, Kenneth et al. (2010) Inhibition of thrombin formation by active site mutated (S360A) activated protein C. J Biol Chem 285:22890-900
Berny, Michelle A; Munnix, Imke C A; Auger, Jocelyn M et al. (2010) Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS One 5:e10415
Smith, Stephen B; Verhamme, Ingrid M; Sun, Mao-fu et al. (2008) Characterization of Novel Forms of Coagulation Factor XIa: independence of factor XIa subunits in factor IX activation. J Biol Chem 283:6696-705

Showing the most recent 10 out of 19 publications